Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 34-41

  Diepstra, Arjan ^a   Niens, M ^a   Te Meerman, G J ^a   Poppema, S ^a   Van Den Berg, A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antigen presentation; Epstein Barr virus; Genetic predisposition; HLA antigens; Hodgkin disease; Pathophysiology

Indexed keywords

CYTOKINE; HLA ANTIGEN; HLA A ANTIGEN;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CELL ACTIVATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; REED STERNBERG CELL; CHROMOSOME 6; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; REVIEW; VIROLOGY; VIRUS INFECTION;

CHROMOSOMES, HUMAN, PAIR 6; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HLA-A ANTIGENS; HODGKIN DISEASE; HUMANS; REED-STERNBERG CELLS;

EID: 21144455688     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. DIEPSTRA A, MAGGIO E, VAN DEN BERG A, POPPEMA, S. Immune dysfunction in classical Hodgkin's lymphoma. In: FINKE JH, BUKOWSKI RM, eds. Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done. Totowa: Humana Press, 2004:315-334.
2. MAGGIO E, VAN DEN BERG A, DIEPSTRA A, KLUIVER J, VISSER L, POPPEMA S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13(Suppl 1):52-56.
3. OHSHIMA K, KARUBE K, HAMASAKI M, SUEFUJI H, TUTIYA T, YAMAGUCHI T, SUZUMIYA J, KIKUCHI, M. Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL. Int J Cancer 2003;20,106:706-712.
4. VAN DEN BERG A, VISSER L, POPPEMA S. High Expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691.
5. SKINNIDER BF, MAK TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
6. GOEDERT JJ, COTE TR, VIRGO P, SCOPPA SM, KINGMA DW, GAIL MH, JAFFE ES, BIGGAR RJ. Spectrum of AIDS-associated malignant disorders. Lancet 1998;20,351:1833-1839.
7. JARRETT RF. Viruses and Hodgkin's lymphoma. Ann Oncol 2002;13(Suppl 1):23-29.
8. KLEIN J, SATO A. The HLA system. First of two parts. N Engl J Med 2000;343:702-709.
9. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999;401:921-923.
10. TZANKOV A, ZIMPFER A, PEHRS AC, LUGLI A, WENT P, MAURER R, PILERI S, DIRNHOFER S. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-1147.
11. HSU SM, HSU PL. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncog 1994;5:213-245.
12. OUDEJANS JJ, JIWA NM, KUMMER JA, HORSTMAN A, VOS W, BAAK JP, KLUIN PM, VAN DER V, WALBOOMERS JM, MEIJER CJ. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and - negative Hodgkin's disease. Blood 1996;87:3844-3851.
13. MURRAY PG, CONSTANDINOU CM, CROCKER J, YOUNG LS, AMBINDER RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998;92:2477-2483.
14. LEE SP, CONSTANDINOU CM, THOMAS WA, CROOM-CARTER D, BLAKE NW, MURRAY PG, CROCKER J, RICKINSON AB. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 1998; 92:1020-1030.
15. POPPEMA S, POTTERS M, EMMENS R, VISSER L, VAN DEN BERG A. Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 1999;36:253-259.
16. WANG RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-276.
17. VOO KS, FU T, HESLOP HE, BRENNER MK, ROONEY CM, WANG RF. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res 2002;62:7195-7199.
18. GRUSS HJ, PINTO A, DUYSTER J, POPPEMA S, HERRMANN F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156-163.
19. MEIJ P, LEEN A, RICKINSON AB, VERKOEIJEN S, VERVOORT MB, BLOEMENA E, MIDDELDORP JM. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 2002;99:93-99.
20. LEE SP, TIERNEY RJ, THOMAS WA, BROOKS JM, RICKINSON AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997;158:3325-3334.
21. GLASER SL, HSU JL. Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res 2002;26:261-269.
22. GLASER SL, LIN RJ, STEWART SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-382.
23. DEVORE JW, DOAN CA. Studies in Hodgkin's syndrome. XII. Hereditary and epidemiologic espects. Ann Intern Med 1957;47:300-316.
24. HALAZUN JF, KERR SE, LUKENS JN. Hodgkin's disease in three children from an amish kindred. J Pediatr 1972; 80:289-291.
25. CREAGAN ET, FRAUMENI JF. Familial Hodgkin's disease. Lancet 1972;2:547.
26. FERRARIS AM, RACCHI O, RAPEZZI D, GAETANI GF, BOFFETTA P. Familial Hodgkin's disease: a disease of young adulthood? Ann Hematol 1997;74:131-134.
27. RAZIS DV, DIAMOND HD, CRAVER LF. Familial Hodgkin's disease: its significance and implications. Ann Intern Med 1959;51:933-971.
28. MANIGAND G, MACREZ C, CHOME J, BOSSON C, DELAMARE J, DEPARIS M. Familial Hodgkin's disease. Presse Med 1964;72:1871-1874.
29. GRUFFERMAN S. Clustering and aggregation of exposures in Hodgkin's disease. Cancer 1977;39(Suppl 4):1829-1833.
30. MACK TM, COZEN W, SHIBATA DK, WEISS LM, NATHWANI BN, HERNANDEZ AM, TAYLOR CR, HAMILTON AS, DEAPEN DM, RAPPAPORT EB. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995;332:413-418.
31. MARSHALL WH, BARNARD JM, BUEHLER SK, CRUMLEY J, LARSEN B. HLA in familial Hodgkin's disease. Results and a new hypothesis. Int J Cancer 1977;19:450-455.
32. GREENE MH, MCKEEN EA, LI FP, BLATTNER WA, FRAUMENI JF. HLA antigens in familial Hodgkin's disease. Int J Cancer 1979;23:777-780.
33. CONTE R, LAURIA F, ZUCCHELLI P. HLA in familial Hodgkin's disease. J Immunogenet 1983;10:251-255.
34. HORS J, DAUSSET J. HLA and susceptibility to Hodgkin's disease. Immunol Rev 1983;70:167-192.
35. HORS J, STEINBERG G, ANDRIEU JM, JACQUILLAT C, MINEV M, MESSERSCHMITT J, MALINVAUD G, FUMERON F, DAUSSET J, BERNARD J. HLA genotypes in familial Hodgkin's disease. Excess of HLA identical affected subs. Eur J Cancer 1980;16:809-815.
36. KALIDI I, MASSET M, GONY J, MARCELLI A, JEANNET M, IRLE C, BAUTERS, F., TCHERNIA, G., TURPIN, F., GISSELBRECHT, C. MHC related genetic susceptibility to Hodgkin's disease. Nouv Rev Fr Hematol 1989;31:149-152.
37. CHAKRAVARTI A, HALLORAN SL, BALE SJ, TUCKER MA. Etiological heterogeneity in Hodgkin's disease: HLA linked and unlinked determinants of susceptibility independent of histological concordance. Genet Epidemiol 1986;3:407-415.
38. TORRES A, MARTINEZ F, GOMEZ P, GOMEZ C, GARCIA JM, NUNEZ-ROLDAN A. Simultaneous Hodgkin's disease in three siblings with identical HLA-genotype. Cancer 1980;46:83 8-843.
39. ROBERTSON SJ, LOWMAN JT, GRUFFERMAN S, KOSTYU D, VAN DER HORST CM, MATTHEWS TJ, BOROWITZ MJ, BIGNER SH. Familial Hodgkin's disease. A clinical and laboratory investigation. Cancer 1987;59:1314-1319.
40. HARTY LC, LIN AY, GOLDSTEIN AM, JAFFE ES, CARRINGTON M, TUCKER MA, MODI WS. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 2002;99:690-693.
41. BERBERICH FR, BERBERICH MS, KING MC, ENGLEMAN EG, GRUMET FC. Hodgkin's disease susceptibility: linkage to the HLA locus demonstrated by a new concordance method. Hum Immunol 1983;6:207-217.
42. SHUGART YY, HEMMINKI K, VAITTINEN P, KINGMAN A, DONG C. A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet 2000;106:553-556.
43. PERLIN E, O'DONNELL M. Letter: another observation of increased frequency of HL-a 5 and HL-a 8 in Hodgkin's disease. Am J Clin Pathol 1975;64:277-278.
44. VUKOVIC I, SUSAKOVIC N, DUJIC A, STOJIMIROVIC E, MARKOVIC V. HLA system antigens in Hodgkin's disease in children. Bill Hematol Transfuz 1977;5:59-65.
45. BJORKHOLM M, HOLM G, JOHANSSON B, MELLSTEDT H, MOLLER E. A prospective study of HL-A antigen phenotypes and lymphocyte abnormalities in Hodgkin's disease. Tissue Antigens 1975;6:247-256.
46. HORNMARK-STENSTAM B, LANDBERG T, LOW B. HLA antigens in Hodgkin's disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 1978;17:283-288.
47. HANSEN JA, YOUNG CW, WHITSETT C, CASE DC, JERSILD C, GOOD RA, DUPONT B. HLA and MLC typing in patients with Hodgkin's disease. Prog Clin Biol Res 1977;16:217-227.
48. HAFEZ MM, EL WEHEDY GF, EL KHOLY NM, EL SHAWAF IM, MAHMOUD ME, GAMIL TM. The value of HLA phenotypes in the prognosis of Hodgkin's lymphoma. Int J Cancer 1985;36:19-22.
49. OSOBA D, FALK JA, SOUSAN P, CIAMPI A, TILL JE. The prognostic value of HLA phenotypes in Hodgkin's disease. Cancer 1980;46:1825-1832.
50. PRAZAK J, CHYTRY P, HERMANSKA Z. Relation of HLA antigens to prognosis in Hodgkin's disease. Vnitr Lek 1991;37:781-788.
51. BODMER JG, TONKS S, OZA AM, LISTER TA, BOOMER WF. HLA-DP based resistance to Hodgkin's disease. Lancet 1989;1:1455-1456.
52. OZA AM, TONKS S, LIM J, FLEETWOOD MA, LISTER TA, BOOMER JG. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. Cancer Res 1994;54:5101-5105.
53. TONKS S, OZA AM, LISTER TA, BOOMER JG. Association of HLA-DPB with Hodgkin's disease. Lancet 1992;340:968-969.
54. ALEXANDER FE, JARRETT RF, CARTWRIGHT RA, ARMSTRONG AA, GOKHALE DA, KANE E, GRAY D, LAWRENCE DJ, TAYLOR GM. Epstein-Barr virus and HLA-DPB1-*0301 in young adult Hodgkin's disease: evidence for inherited susceptibility to Epstein-Barr virus in cases that are EBV(+ve). Cancer Epidemiol Biomarkers Prev 2001;10:705-709.
55. KLITZ W, ALDRICH CL, FILDES N, HORNING SJ, BEGOVICH AB. Localization of Predisposition to Hodgkin disease in the HLA class II region. Am J Hum Genet 1994;54:497-505.
56. TAYLOR GM, GOKHALE DA, CROWTHER D, WOLL P, HARRIS M, ALEXANDER F, JARRETT R, CARTWRIGHT RA. Increased frequency of HLA-DPB1*0301 in Hodgkin's disease suggests that susceptibility is HVR-sequence and subtype-associated. Leukemia 1996;10:854-859.
57. TAYLOR GM, GOKHALE DA, CROWTHER D, WOLL PJ, HARRIS M, RYDER D, AYRES M, RADFORD JA. Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. Br J Cancer 1999;80:1405-1411.
58. BEGOVICH AB, MCCLURE GR, SURAJ VC, HELMUTH RC, FILDES N, BUGAWAN TL, ERLICH HA, KLITZ W. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992;148:249-258.
59. DIEPSTRA A, NIENS M, VELLENGA E, TE MEERMAN GJ, SCHAAPVELD M, NOLTE IM, VAN IMHOFF GW, POPPEMA S. Population based genotyping of the human leukocyte antigen (HLA) in Hodgkin lymphoma: EBV positive HL is associated with HLA class I and EBV negative HL is associated with HLA class III. Blood 2004;104(11 [part 1 of 2 parts]):126 (abstract).